Genetic Analysis AS (XSAT:GEAN)

Sweden · Delayed Price · Currency is SEK · Price in NOK

0.760

+0.030 (4.11%)

At close: Dec 5, 2025

38.18% (1Y)

Market Cap	48.90M
Revenue (ttm)	20.45M
Net Income (ttm)	-9.20M
Shares Out	69.09M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,155
Average Volume	36,554
Open	0.760
Previous Close	0.730
Day's Range	0.745 - 0.760
52-Week Range	0.430 - 2.600
Beta	2.39
RSI	46.15
Earnings Date	Nov 27, 2025

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Colle... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2008

Employees 16

Stock Exchange Spotlight Stock Market

Ticker Symbol GEAN

Full Company Profile

Financial Performance

In 2024, Genetic Analysis AS's revenue was 20.68 million, a decrease of -10.71% compared to the previous year's 23.16 million. Losses were -14.77 million, -37.99% less than in 2023.

Financial numbers in NOK Financial Statements

News

There is no news available yet.